Literature DB >> 8847897

Retroviral transduction of hematopoietic progenitor cells with mutant p53 promotes survival and proliferation, modifies differentiation potential and inhibits apoptosis.

Y Shounan1, A Dolnikov, K L MacKenzie, M Miller, Y Y Chan, G Symonds.   

Abstract

Mutations in the p53 tumor suppressor gene have been shown to be associated with many human tumors and various leukemias and lymphomas. To examine whether constitutive overexpression of mutant p53 can effect transformation of normal hematopoietic cells, a mutant p53 gene was introduced into normal murine bone marrow hematopoietic cells by retroviral gene transfer. Compared to vector alone-infected cells, hematopoietic progenitor cells transduced with mutant p53 showed increased proliferative potential, enhanced cloning efficiencies and a modified differentiation pattern in vitro. In addition, mutant p53-transduced hematopoietic cells were more resistant to loss of viability and/or induction of apoptosis when cultured in a low concentration of serum or in the absence of both growth factors and serum. These effects occurred rapidly with no apparent contributory secondary events. No permanent cell lines or growth factor-independent cell strains were obtained. The results indicate that introduction of mutant p53 into normal hematopoietic cells in vitro contributes to transformation, including enhanced proliferative potential, modified differentiation and the suppression of apoptosis in these cells.

Entities:  

Mesh:

Year:  1996        PMID: 8847897

Source DB:  PubMed          Journal:  Leukemia        ISSN: 0887-6924            Impact factor:   11.528


  9 in total

Review 1.  Using mice to examine p53 functions in cancer, aging, and longevity.

Authors:  Lawrence A Donehower
Journal:  Cold Spring Harb Perspect Biol       Date:  2009-11-04       Impact factor: 10.005

2.  The Regulation of Aging and Longevity: A New and Complex Role of p53.

Authors:  Zhaohui Feng; Meihua Lin; Rui Wu
Journal:  Genes Cancer       Date:  2011-04

Review 3.  Gfi1-cells and circuits: unraveling transcriptional networks of development and disease.

Authors:  James D Phelan; Noah F Shroyer; Tiffany Cook; Brian Gebelein; H Leighton Grimes
Journal:  Curr Opin Hematol       Date:  2010-07       Impact factor: 3.284

Review 4.  The p53 tumor suppressor protein regulates hematopoietic stem cell fate.

Authors:  Takashi Asai; Yan Liu; Narae Bae; Stephen D Nimer
Journal:  J Cell Physiol       Date:  2011-09       Impact factor: 6.384

5.  The impact of altered p53 dosage on hematopoietic stem cell dynamics during aging.

Authors:  Melissa Dumble; Lynette Moore; Stuart M Chambers; Hartmut Geiger; Gary Van Zant; Margaret A Goodell; Lawrence A Donehower
Journal:  Blood       Date:  2006-10-10       Impact factor: 22.113

6.  Roles of AML1/RUNX1 in T-cell malignancy induced by loss of p53.

Authors:  Kimiko Shimizu; Kazutsune Yamagata; Mineo Kurokawa; Shuki Mizutani; Yukiko Tsunematsu; Issay Kitabayashi
Journal:  Cancer Sci       Date:  2013-06-20       Impact factor: 6.716

7.  p53 regulates hematopoietic stem cell quiescence.

Authors:  Yan Liu; Shannon E Elf; Yasuhiko Miyata; Goro Sashida; Yuhui Liu; Gang Huang; Silvana Di Giandomenico; Jennifer M Lee; Anthony Deblasio; Silvia Menendez; Jack Antipin; Boris Reva; Andrew Koff; Stephen D Nimer
Journal:  Cell Stem Cell       Date:  2009-01-09       Impact factor: 24.633

8.  A polymorphism in the tumor suppressor p53 affects aging and longevity in mouse models.

Authors:  Yuhan Zhao; Lihua Wu; Xuetian Yue; Cen Zhang; Jianming Wang; Jun Li; Xiaohui Sun; Yiming Zhu; Zhaohui Feng; Wenwei Hu
Journal:  Elife       Date:  2018-03-20       Impact factor: 8.140

9.  Loss of <i>Nupr1</i> promotes engraftment by tuning the quiescence threshold of hematopoietic stem cell repository via regulating p53-checkpoint pathway.

Authors:  Tongjie Wang; Chengxiang Xia; Qitong Weng; Kaitao Wang; Yong Dong; Sha Hao; Fang Dong; Xiaofei Liu; Lijuan Liu; Yang Geng; Yuxian Guan; Juan Du; Tao Cheng; Hui Cheng; Jinyong Wang
Journal:  Haematologica       Date:  2022-01-01       Impact factor: 9.941

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.